Lutz WK - Search Results

1

Decreased tumor surveillance in perforin-deficient mice.

van den Broek ME, Kägi D, Ossendorp F, Toes R, Vamvakas S, Lutz WK, Melief CJ, Zinkernagel RM, Hengartner H. van den Broek ME, et al. Among authors: lutz wk. J Exp Med. 1996 Nov 1;184(5):1781-90. doi: 10.1084/jem.184.5.1781. J Exp Med. 1996. PMID: 8920866 Free PMC article.

2

Haemophilic knee arthropathy: long-term outcome after total knee replacement.

Zingg PO, Fucentese SF, Lutz W, Brand B, Mamisch N, Koch PP. Zingg PO, et al. Knee Surg Sports Traumatol Arthrosc. 2012 Dec;20(12):2465-70. doi: 10.1007/s00167-012-1896-7. Knee Surg Sports Traumatol Arthrosc. 2012. PMID: 22293897 Free article.

3

Effect of Omeprazole and Dextromethorphan on the Urinary Metabolic Ratio of Flurbiprofen.

Vogl S, Steinfath M, Lutz WK, Schönfelder G. Vogl S, et al. Among authors: lutz wk. Basic Clin Pharmacol Toxicol. 2016 Jun;118(6):496-8. doi: 10.1111/bcpt.12536. Epub 2016 Jan 14. Basic Clin Pharmacol Toxicol. 2016. PMID: 26617075 Free article. No abstract available.

4

Correction: CYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drug.

Vogl S, Lutz RW, Schönfelder G, Lutz WK. Vogl S, et al. Among authors: lutz wk. PLoS One. 2015 Apr 13;10(4):e0126329. doi: 10.1371/journal.pone.0126329. eCollection 2015. PLoS One. 2015. PMID: 25875957 Free PMC article. No abstract available.

5

CYP2C9 genotype vs. metabolic phenotype for individual drug dosing--a correlation analysis using flurbiprofen as probe drug.

Vogl S, Lutz RW, Schönfelder G, Lutz WK. Vogl S, et al. Among authors: lutz wk. PLoS One. 2015 Mar 16;10(3):e0120403. doi: 10.1371/journal.pone.0120403. eCollection 2015. PLoS One. 2015. PMID: 25775139 Free PMC article.

6

Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.

Kroiss M, Quinkler M, Lutz WK, Allolio B, Fassnacht M. Kroiss M, et al. Among authors: lutz wk. Clin Endocrinol (Oxf). 2011 Nov;75(5):585-91. doi: 10.1111/j.1365-2265.2011.04214.x. Clin Endocrinol (Oxf). 2011. PMID: 21883349 Review.

7

Strategies in case of positive in vivo results in genotoxicity testing.

Thybaud V, Macgregor JT, Müller L, Crebelli R, Dearfield K, Douglas G, Farmer PB, Gocke E, Hayashi M, Lovell DP, Lutz WK, Marzin D, Moore M, Nohmi T, Phillips DH, Van Benthem J. Thybaud V, et al. Among authors: lutz wk. Mutat Res. 2011 Aug 16;723(2):121-8. doi: 10.1016/j.mrgentox.2010.09.002. Epub 2010 Sep 17. Mutat Res. 2011. PMID: 20854927

8

Quantification of cortisol and 6 beta-hydroxycortisol in human urine by LC-MS/MS, and gender-specific evaluation of the metabolic ratio as biomarker of CYP3A activity.

Lutz U, Bittner N, Ufer M, Lutz WK. Lutz U, et al. Among authors: lutz wk. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Jan 1;878(1):97-101. doi: 10.1016/j.jchromb.2009.11.023. J Chromatogr B Analyt Technol Biomed Life Sci. 2010. PMID: 19959402

9

The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?

Lutz WK. Lutz WK. Toxicol Lett. 2009 Nov 12;190(3):239-42. doi: 10.1016/j.toxlet.2009.07.032. Epub 2009 Aug 18. Toxicol Lett. 2009. PMID: 19695319

10

Biological significance of DNA adducts: comparison of increments over background for various biomarkers of genotoxicity in L5178Y tk(+/-) mouse lymphoma cells treated with hydrogen peroxide and cumene hydroperoxide.

Brink A, Richter I, Lutz U, Wanek P, Stopper H, Lutz WK. Brink A, et al. Among authors: lutz wk. Mutat Res. 2009 Aug;678(2):123-8. doi: 10.1016/j.mrgentox.2009.06.001. Epub 2009 Jun 16. Mutat Res. 2009. PMID: 19539047

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

161 results

Search Page